Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib

References

• Lannering B, Sandström PE, Holm S, Lundgren J, Pfeifer S, Samuelsson U. Classification, incidence and survival analyses of children with CNS tumours diagnosed in Sweden 1984-2005. Acta Paediatr. 2009;98(10):1620–1627. doi:10.1111/j.1651-2227.2009.01417.x.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(Suppl Supplement_5):v1–v100. doi:10.1093/neuonc/noz150.
   PubMedGoogle Scholar
• Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569–83.e5. doi:10.1016/j.ccell.2020.03.011.
   PubMed Web of Science ®Google Scholar
• Van Den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective. Acta Neuropathol. 2010;120(3):297–304. doi:10.1007/s00401-010-0725-7.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Agnihotri S, Broniscer A. Childhood brain tumors: current management, biological insights, and future directions. J Neurosurg Pediatr. 2019;23(3):261–273. doi:10.3171/2018.10.PEDS18377.
   PubMed Web of Science ®Google Scholar
• Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the children’s oncology group. Neurosurgery. 2011;68(6):1548–1554. discussion 54–5. doi:10.1227/NEU.0b013e318214a66e.
   PubMed Web of Science ®Google Scholar
• Farazdaghi MK, Katowitz WR, Avery RA. Current treatment of optic nerve gliomas. Curr Opin Ophthalmol. 2019;30(5):356–363. doi:10.1097/ICU.0000000000000587.
   PubMed Web of Science ®Google Scholar
• Krishnatry R, Zhukova N, Guerreiro Stucklin AS, Pole JD, Mistry M, Fried I. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: a population-based study. Cancer. 2016;122(8):1261–1269. doi:10.1002/cncr.29907.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27(22):3691–3697. doi:10.1200/JCO.2008.21.2738.
   PubMed Web of Science ®Google Scholar
• Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–8677. doi:10.1158/0008-5472.CAN-08-2097.
   PubMed Web of Science ®Google Scholar
• Pfister S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739–1749. doi:10.1172/JCI33656.
   PubMed Web of Science ®Google Scholar
• Tomic TT, Olausson J, Wilzen A, Sabel M, Truve K, Sjogren H. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS One. 2017;12(4):e0175638. doi:10.1371/journal.pone.0175638.
   PubMed Web of Science ®Google Scholar
• Helgager J, Lidov HG, Mahadevan NR, Kieran MW, Ligon KL, Alexandrescu S. A novel GIT2-BRAF fusion in pilocytic astrocytoma. Diagn Pathol. 2017;12(1):82. doi:10.1186/s13000-017-0669-5.
   PubMedGoogle Scholar
• Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 2011;121(6):763–774. doi:10.1007/s00401-011-0817-z.
   PubMed Web of Science ®Google Scholar
• Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45(8):927–932. doi:10.1038/ng.2682.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013;45(6):602–612.
   PubMed Web of Science ®Google Scholar
• Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108(1):193–198. doi:10.1038/bjc.2012.535.
   PubMed Web of Science ®Google Scholar
• Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34(17):1978–1986. doi:10.1200/JCO.2015.65.3576.
   PubMed Web of Science ®Google Scholar
• Bongaarts A, Van Scheppingen J, Korotkov A, Mijnsbergen C, Anink JJ, Jansen FE. The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas. Brain. 2020;143(1):131–149. doi:10.1093/brain/awz370.
   PubMedGoogle Scholar
• Jones DT, Gronych J, Lichter P, Witt O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2012;69(11):1799–1811. doi:10.1007/s00018-011-0898-9.
   PubMed Web of Science ®Google Scholar
• Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun. 2019;10(1):4343. doi:10.1038/s41467-019-12187-5.
   PubMed Web of Science ®Google Scholar
• Pehlivan KC, Malicki DM, Levy ML, Crawford JR. TPM3-NTRK1 fusion in a pleomorphic xanthoastrocytoma presenting with haemorrhage in a child. BMJ Case Rep. 2020;13(3). doi:10.1136/bcr-2020-234347.
   Google Scholar
• Mobark NA, Alharbi M, Alhabeeb L, AlMubarak L, Alaljelaify R, AlSaeed M. Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia. PLoS One. 2020;15(1):e0228356. doi:10.1371/journal.pone.0228356.
   PubMed Web of Science ®Google Scholar
• Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 2016;131(6):833–845. doi:10.1007/s00401-016-1539-z.
   PubMed Web of Science ®Google Scholar
• Torre M, Jessop N, Hornick JL, Alexandrescu S. Expanding the spectrum of pediatric NTRK-rearranged fibroblastic tumors to the central nervous system: a case report with RBPMS-NTRK3 fusion. Neuropathology. 2018;38(6):624–630. doi:10.1111/neup.12513.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34. doi:10.1158/2159-8290.CD-14-0765.
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328. doi:10.1016/j.tibs.2011.03.006.
   PubMed Web of Science ®Google Scholar
• Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P. The paradox of Akt-mTOR interactions. Front Oncol. 2013;3:165. doi:10.3389/fonc.2013.00165.
   PubMedGoogle Scholar
• Tateishi K, Nakamura T, Yamamoto T. Molecular genetics and therapeutic targets of pediatric low-grade gliomas. Brain Tumor Pathol. 2019;36(2):74–83. doi:10.1007/s10014-019-00340-3.
   PubMed Web of Science ®Google Scholar
• Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66. doi:10.1016/j.pharmthera.2017.02.006.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017;19(6):750–761. doi:10.1093/neuonc/now209.
   PubMed Web of Science ®Google Scholar
• Hastings R, Howell R, Bricarelli F D, Kristoffersson U, Cavani S. FISH on histological sections of solid tumors: E.C.A. Recommendations. E.C.A European Cytogeneticists Association Newsletter 29. 2012 Jan. [accessed 2020 Nov 2] https://www.e-c-a.eu/en/GUIDELINES.html
   Google Scholar
• Chetty R. Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes. J Clin Pathol. 2019;72(3):187–190. doi:10.1136/jclinpath-2018-205672.
   PubMed Web of Science ®Google Scholar
• Pattwell SS, Konnick EQ, Liu YJ, Yoda RA, Sekhar LN, Cimino PJ. Neurotrophic receptor tyrosine kinase 2 (NTRK2) alterations in low-grade gliomas: report of a novel gene fusion partner in a pilocytic astrocytoma and review of the literature. Case Rep Pathol. 2020;2020:5903863. doi:10.1155/2020/5903863.
   PubMed Web of Science ®Google Scholar
• Kowianski P, Lietzau G, Czuba E, Waskow M, Steliga A, Morys J. BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol. 2018;38(3):579–593. doi:10.1007/s10571-017-0510-4.
   PubMed Web of Science ®Google Scholar
• Yuasa K, Omori K, Yanaka N. Binding and phosphorylation of a novel male germ cell-specific cGMP-dependent protein kinase-anchoring protein by cGMP-dependent protein kinase Ialpha. J Biol Chem. 2000;275(7):4897–4905. doi:10.1074/jbc.275.7.4897.
   PubMed Web of Science ®Google Scholar
• Donner I, Katainen R, Tanskanen T, Kaasinen E, Aavikko M, Ovaska K. Candidate susceptibility variants for esophageal squamous cell carcinoma. Genes Chromosomes Cancer. 2017;56(6):453–459. doi:10.1002/gcc.22448.
   PubMed Web of Science ®Google Scholar
• Lopez GY, Perry A, Harding B, Li M, Santi M. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. Neuropathol Appl Neurobiol. 2019;45(2):174–178. doi:10.1111/nan.12503.
   PubMed Web of Science ®Google Scholar
• Jones KA, Bossler AD, Bellizzi AM, Snow AN. BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior. Cold Spring Harb Mol Case Stud. 2019;5(2). doi:10.1101/mcs.a003855.
   Web of Science ®Google Scholar
• Torre M, Vasudevaraja V, Serrano J, Delorenzo M, Malinowski S, Pages M. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathologica Communications. 2020;8(1):1–14. doi:10.1186/s40478-020-00980-z.
   PubMed Web of Science ®Google Scholar
• Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32(1):147–153. doi:10.1038/s41379-018-0118-3.
   PubMed Web of Science ®Google Scholar
• Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–450.
   PubMed Web of Science ®Google Scholar
• Coulier F, Martin-Zanca D, Ernst M, Barbacid M. Mechanism of activation of the human trk oncogene. Mol Cell Biol. 1989;9(1):15–23. doi:10.1128/MCB.9.1.15.
   PubMed Web of Science ®Google Scholar
• Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14(12):735–748. doi:10.1038/nrclinonc.2017.127.
   PubMed Web of Science ®Google Scholar
• Huang YZ, McNamara JO. Mutual regulation of src family kinases and the neurotrophin receptor TrkB. J Biol Chem. 2010;285(11):8207–8217. doi:10.1074/jbc.M109.091041.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–1235. doi:10.1126/science.1220834.
   PubMed Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. doi:10.1038/s41571-018-0113-0.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Larotrectinib: first global approval. Drugs. 2019;79(2):201–206. doi:10.1007/s40265-018-1044-x.
   PubMed Web of Science ®Google Scholar
• Federman N, McDermott R. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Expert Rev Clin Pharmacol. 2019;12(10):931–939. doi:10.1080/17512433.2019.1661775.
   PubMed Web of Science ®Google Scholar
• Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705–714. doi:10.1016/S1470-2045(18)30119-0.
   PubMed Web of Science ®Google Scholar
• DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018;124(21):4241–4247. doi:10.1002/cncr.31701.
   PubMed Web of Science ®Google Scholar
• Busse TM, Roth JJ, Wilmoth D, Wainwright L, Tooke L, Biegel JA. Copy number alterations determined by single nucleotide polymorphism array testing in the clinical laboratory are indicative of gene fusions in pediatric cancer patients. Genes Chromosomes Cancer. 2017;56(10):730–749. doi:10.1002/gcc.22477.
   PubMed Web of Science ®Google Scholar
• Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol. 2009;19(3):449–458. doi:10.1111/j.1750-3639.2008.00225.x.
   PubMed Web of Science ®Google Scholar
• Roth JJ, Santi M, Rorke-Adams LB, Harding BN, Busse TM, Tooke LS. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet. 2014;207(4):111–123. doi:10.1016/j.cancergen.2014.03.002.
   PubMed Web of Science ®Google Scholar
• Dougherty MJ, Tooke LS, Sullivan LM, Hakonarson H, Wainwright LM, Biegel JA. Clinical utilization of high-resolution single nucleotide polymorphism based oligonucleotide arrays in diagnostic studies of pediatric patients with solid tumors. Cancer Genet. 2012;205(1–2):42–54. doi:10.1016/j.cancergen.2012.01.014.
   PubMed Web of Science ®Google Scholar
• Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8(1):30.
   PubMed Web of Science ®Google Scholar
• Hsiao SJ, Zehir A, Sireci AN, Aisner DL. Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy. J Mol Diagn. 2019;21(4):553–571. doi:10.1016/j.jmoldx.2019.03.008.
   PubMed Web of Science ®Google Scholar
• Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW. TRK fusion cancers in children: a clinical review and recommendations for screening. J Clin Oncol. 2019;37(6):513–524. doi:10.1200/JCO.18.00573.
   PubMed Web of Science ®Google Scholar
• Solomon JP, Benayed R, Hechtman JF, Ladanyi M. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019;30(Suppl_8):viii16–viii22. doi:10.1093/annonc/mdz384.
   Google Scholar
• Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845–4854. doi:10.1038/onc.2014.406.
   PubMed Web of Science ®Google Scholar